Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: September 24, 2022

Details for Patent: 8,735,380

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,735,380 protect, and when does it expire?

Patent 8,735,380 protects ELLA and is included in one NDA.

This patent has thirty-four patent family members in twenty-six countries.

Summary for Patent: 8,735,380
Title:Ulipristal acetate tablets
Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
Inventor(s): Gainer; Erin (Paris, FR), Guillard; Helene (Paris, FR), Gicquel; Denis (Orgeval, FR), Henrion; Marianne (Paris, FR), Gnakamene; Celine (Paris, FR)
Assignee: Laboratoire HRA Pharma (Paris, FR)
Application Number:13/140,219
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,735,380
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Device;

Drugs Protected by US Patent 8,735,380

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,735,380

PCT Information
PCT FiledDecember 08, 2009PCT Application Number:PCT/EP2009/066652
PCT Publication Date:June 17, 2010PCT Publication Number: WO2010/066749

International Family Members for US Patent 8,735,380

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009326084 See Plans and Pricing
Canada 2745084 See Plans and Pricing
China 102245173 See Plans and Pricing
China 105267168 See Plans and Pricing
Colombia 6400186 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.